key: cord-0907269-o29f7ode
authors: Cihan, Murat; Doğan, Özlem; Ceran Serdar, Ceyhan; Altunçekiç Yıldırım, Arzu; Kurt, Celali; Serdar, Muhittin A.
title: Kynurenine pathway in Coronavirus disease (COVID‐19): Potential role in prognosis
date: 2022-01-29
journal: J Clin Lab Anal
DOI: 10.1002/jcla.24257
sha: 595750b7f7e97b86f0ebfa56d493090855ed194c
doc_id: 907269
cord_uid: o29f7ode

BACKGROUND: It is known that inflammatory responses play an important role in the pathophysiology of COVID‐19. AIMS: In this study, we aimed to examine the role of kynurenine (KYN) metabolism on the severity of COVID‐19 disease AQ5. MATERIALS & METHODS: Seventy COVID‐19 patients of varying severity and 30 controls were included in the study. In addition to the classical laboratory parameters, KYN, tryptophan (TRP), kynurenic acid (KYNA), 3 hydroxykynurenine (3OHKYN), quinolinic acid (QA), and picolinic acid (PA) were measured with mass spectrometry. RESULTS: TRP, KYN, KYN:TRP ratio, KYNA, 3OHKYN, PA, and QA results were found to be significantly different in COVID‐19 patients (p < 0.001 for all). The KYN:TRP ratio and PA of severe COVID‐19 patients was statistically higher than that of mild‐moderate COVID‐19 patients (p < 0.001 for all). When results were examined, statistically significant correlations with KYN:TRP ratio, IL‐6, ferritin, and procalcitonin were only found in COVID‐19 patients. ROC analysis indicated that highest AUC values were obtained by KYN:TRP ratio and PA (0.751 vs 0.742). In determining the severity of COVID‐19 disease, the odd ratios (and confidence intervals) of KYN:TRP ratio and PA levels that were adjusted according to age, gender, and comorbidity were determined to be 1.44 (1.1–1.87, p = 0.008) and 1.06 (1.02–1.11, p = 0.006), respectively. DISCUSSION & CONCLUSION: According to the results of this study, KYN metabolites play a role in the pathophysiology of COVID‐19, especially KYN:TRP ratio and PA could be markers for identification of severe COVID‐19 cases.

The disease may present with heterogeneous and varied settings, ranging from an asymptomatic or mild upper respiratory tract disease to severe cytokine storm, acute respiratory distress syndrome (ARDS), multiple organ failure, and even severe viral pneumonia that can cause death. It is known that aggressive inflammatory responses play an important role in the pathophysiology of COVID- 19, along with the pathology that frequently occurs in the airways. Therefore, disease severity in patients is not only related to viral infection but also related to host response. [2] [3] [4] In many cases, patients recover following the immune response to the infection. However, in some patients, a different type of immune response is activated which mediates diffuse lung inflammation and triggers a cytokine storm. Higher levels of IL-2, IL-7, IL-10, granulocyte colony stimulating factor (G-CSF), IP-10, MCP1, macrophage inflammatory protein 1α (MIP1α), and tumor necrosis factor (TNF) were detected, especially in severe COVID-19 patients requiring intensive care. It has been shown that especially increasing IL-6 levels in these patients over time are associated with mortality. 5 Tryptophan (TRP) is oxidized by tryptophan 2, 3-dioxygenase in liver cells. The kynurenine pathway, which hosts KYN and its degradation products, is a metabolic pathway that leads to the production of nicotinamide adenine dinucleotide (NAD + ), which is an important energy source. 6 In addition, kynurenine, whose conversion is catalyzed by tryptophan dioxygenase (TDO) and indoleamine 2,3-dioxygenase (IDO), is involved in the regulation of immune system and neurological functions in many different tissues. 6, 7 It has been shown that the KYN pathway plays an important role in the regulation of the immune system. 8 This pathway is regulated by 3 enzymes, tryptophan-2,3-dioxygenase (TDO), and indoleamine-pyrrole 2,3-dioxygenase I and 2 (IDO-1 and IDO-2), which synchronously control the rate limiting first step. TRP is first transformed into to N-formylkynurenine (NFK) by IDO-1, and then, NFK is degraded by formamidase to KYN. KYN is converted to kynurenic acid (KYNA) through transamination or to 3 hydroxykynurenine (3OHKYN) through hydroxylation. In the next stages, it nonenzymatically transforms into 3 hydroxyanthranilic acid to form quinolinic acid (QA) and picolinic acid (PA) (Figure 1 ). 9, 10 COVID-19 or other infections lead to increases in interferon gamma (IFNγ), interleukin 1, 2, 6, and tumor necrosis factor-Alpha (TNFα) in macrophages, resulting in increased expression of IDO and induction of the KYN pathway. 7 Activation of the KYN pathway leads to certain reactions.

1. KYN binds to and activates the aryl hydrocarbon receptor (AhR) in both dendritic cells and T cells. This promotes the transformation of T-effector cells into Treg cells and also promotes IDO induction. Thus, it creates a Kyn/AhR/IDO cycle that maintains immunosuppression. 9, 11 AhR is known to play an important role in COVID-19 infection. 12, 13 F I G U R E 1 Metabolites in the KYN pathway and its possible relationship with COVID-19 2. The decrease in TRP activates non-depressed general control 2 (GCN2), by increasing the production of anti-inflammatory cytokines in dendritic cells and macrophages. As a result, it may lead to differentiation and accumulation of Treg cells. 14 3. Changes in the amounts of KYN and its metabolites have been detected in some viral diseases such as HIV, Influenza, and HBV. [15] [16] [17] 4. IDO-1 can lead to immune tolerance independent of its enzymatic activity by acting as a signaling molecule in dendritic cells. 18 KYN pathway metabolites (e.g. KYNA, 3OHKYN, and cinnabarinic acids) exert an anti-infective effect and may support immune tolerance. 19 In general, activation of the KYN pathway occurs in response to inflammation and can increase the severity of the disease by weak- The sample size in the study was calculated using the G-POWER software 3.1.9.2 (Düsseldorf, Germany) as described by Lionetti et al. 7 When alpha and power is selected as 0.05 and 0.9, respectively, the sample size was calculated to be 66 for an effect size of 0.501. Since there were three different COVID-19 groups together with a control group, we decided to use minimum 88 patients in total. Since we thought that there might be a sample size difference between the groups, we considered that it would be appropriate to have 100 patients. Accordingly, patients with mild/moderate pneumonia symptoms, such as fever, muscle/joint pain, cough, sore throat, breath rate <30/ min, and SpO2 (peripheral capillary oxygen saturation) >90 at room temperature, were classified as "Mild-Moderate". Patients with severe pneumonia symptoms such as fever, muscle/joint pain, cough, sore throat, breath rate >30/min and require hospitalization, or clinically compatible patients with SpO2<90 at room temperature, or patients with bilateral diffuse pneumonia findings on CT scan were classified as "Severe". The third group consisted of the COVID-19 patients hospitalized in the ICU.

Counter blood cell analyses were performed on XN 9000 analyzer Shapiro-Wilk test was used to evaluate the distribution of the data.

ANOVA and post hoc Tukey's analyses were used for normally distributed data. Non-normally distributed data were first analyzed with Kruskal-Wallis test and then corrected using Bonferroni. Chisquared test was applied for categorical data such as gender. Results were presented as mean ± SD or median (25%-75% values). In order to determine the independent roles of KYN metabolites in determining the severity of the disease, multivariate analyzes were performed according to age, gender and comorbidity. Receiver Operating Characteristic-ROC-analysis was performed for clinical evaluation, and results were evaluated with area under the ROC curve (AUC). A p-value <0.05 was considered to be statistically significant.

The comorbidity data and laboratory findings of the COVID-19 patient and control groups are presented in Table 1 Figure 2 ).

According to the Spearman correlation analysis results, when the total cases were examined, it was determined that there were statistically significant correlations between KYN metabolites and especially inflammatory markers. As expected, statistically significant positive correlations were found between IL-6 and KYN:TRP ratio ( Table 2) .

When only the correlation results in COVID-19 patients were examined, significant correlations were found between KYN:TRP ratio and IL-6, ferritin, and procalcitonin. However, no significant correlation was found between KYN metabolites and other laboratory parameters in the healthy control group (Table 2) .

When the correlation among the metabolites in the KYN pathway was examined, it was found that there was a statistically significant correlation between some KYN pathway metabolites in both healthy controls and COVID-19 patients and the total group (Table 2) .

When COVID-19 patient group was compared with the healthy control, the ROC analysis results showed that the distinctive feature of "classical laboratory parameters and KYN metabolites" was high.

However, considering the main purpose of the present study, evaluation of the severity of COVID-19 disease, it has been determined that KYN:TRP ratio and PA values are among the KYN metabolite parameters having most substantial differences in severe COVID-19 patients.

It has been evaluated that these two parameters can be used more effectively than other parameters in differentiating severe patients and clarifying the pathophysiology (Figure 3 ). KYN:TRP ratio and PA levels, which were considered to be significant in determining the severity of the disease, were adjusted according to age, gender, and comorbidity using multivariate regression analysis. Accordingly, the odd ratio and confidence intervals of between Kyn metabolites and IL-6 levels. 24 However, in this study, 3OHKYN values were not found to be low. We think that this difference is due to the derivatized method used in this study which is known to be a more sensitive method. In parallel with the previous literature, which reported high levels of cytokines in patients hospitalized in ICUs, high levels were detected especially for IL-6 in COVID-19 patients in the present study. 5 In this study, significant correlations were found between N:L ratio, procalcitonin, CRP, IL-6, and ferritin and some KYN pathway metabolites, especially in the total and COVID-19 patient groups, but no significant correlations were found in the healthy group (Table 2) determining the fatality of COVID-19 patients, fatality was not evaluated in our study. 27 Danlos et al., 28 

The authors declare no competing interests.

All datasets used during the present study are available from the corresponding author on reasonable request. 

Abbreviations: 3OHKYN, 3 Hydroxykynurenine

Alkaline Phosphatase

Intensive Care Unit

Statistical difference with the control group p < 0.05, ($) Statistical difference with the mild-moderate COVID-19 group p < 0.05, (#) statistical

Immunopathology of hyperinflammation in COVID-19

The trinity of COVID-19: immunity, inflammation and intervention

Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China

Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

3-dioxygenase is a key modulator of physiological neurogenesis and anxiety-related behavior in mice

Increased kynurenine-totryptophan ratio in the serum of patients infected with SARS-CoV2: An observational cohort study

Tryptophan-kynurenine pathway is dysregulated in inflammation and immune activation

The coevolution of IDO1 and AhR in the emergence of regulatory T-cells in mammals

Kynurenines and glutamate: multiple links and therapeutic implications

Positive allosteric modulation of indoleamine 2,3-dioxygenase 1 restrains neuroinflammation

Aryl hydrocarbon receptor role in co-ordinating SARS-CoV-2 entry and symptomatology: linking cytotoxicity changes in COVID-19 and cancers; modulation by racial discrimination stress

AhR and IDO1 in pathogenesis of Covid-19 and the "Systemic AhR Activation Syndrome:" a translational review and therapeutic perspectives

Indoleamine 2,3-dioxygenase downregulates T-cell receptor complex ζ-chain and c-Myc, and reduces proliferation, lactate dehydrogenase levels and mitochondrial glutaminase in human T-cells

HIV/Human herpesvirus coinfections: Impact on tryptophan-kynurenine pathway and immune reconstitution

Assessment of neopterin and indoleamine 2,3-dioxygenase activity in patients with seasonal influenza: a pilot study. Influenza Other Respir Viruses

Analysis of tryptophan catabolism in HBV patients by HPLC with programmed wavelength ultraviolet detection

Ido expression by dendritic cells: tolerance and tryptophan catabolism

Cinnabarinic acid, an endogenous agonist of type-4 metabotropic glutamate receptor, suppresses experimental autoimmune encephalomyelitis in mice

A validated UHPLC-MS method for tryptophan metabolites: application in the diagnosis of multiple sclerosis

Mass spectrometry in the clinical laboratory: general principles and guidance; proposed guideline, CLSI C50-P

Liquid chromatography-mass spectrometry methods; approved guideline, CLSI C62-A

alyti cal-Metho d-Valid ation -Guida ncefor-Indus try

COVID-19 infection alters kynurenine and fatty acid metabolism, correlating with IL-6 levels and renal status

Integrative modeling of quantitative plasma lipoprotein, metabolic, and amino acid data reveals a multiorgan pathological signature of SARS-CoV-2 infection

Systemic perturbations in amine and kynurenine metabolism associated with acute SARS-CoV-2 infection and inflammatory cytokine responses

Increased kynurenine indicates a fatal course of COVID-19

Metabolomic analyses of COVID-19 patients unravel stage-dependent and prognostic biomarkers

Expression and regulation of immune-modulatory enzyme indoleamine 2,3-dioxygenase (IDO) by human airway epithelial cells and its effect on T cell activation

Antioxidant activities of some tryptophan metabolites: possible implication for inflammatory diseases